$SRXH With SRX Global moving aggressively into launching actively managed, AI-powered crypto ETFs, Jackson is subject to incredibly strict SEC regulations regarding marketing, signaling, or highlighting specific publicly traded entities on personal feeds.

$HOLO no diluting on rs since april 27,no offering before prior ends conversion and when ends no offering neither because they can't full the market witht this new notes,they would lose the dollar and they couldn't defend price with rs... so ,calm time before the end to convert old notes,then the run,only infinite patience is needed but will be worth...

$CRVS Moore!

$ADTX Well, finally, a news released on progress. Also, FYI, it can be found on company's LinkedIn acct, where you can be redirected to it from Ignite's homepage and it states, "continuing to expand lists of collaborations with leading cancer centers". As you may know, the cancer center that Ignite Proteomics is collaborating breast cancer research with is Memorial Sloan Kettering Cancer Center, "ranked #1 globally in oncology and #2 nationally in cancer."

$IREN Funds will start taking positions this week as the mid-terms come to a close. November will be a cracking month.

$SIVE Sivers has secured its first formal mass-production order from a strategic LiDAR client, with shipments expected to begin in the fourth quarter. Over the product's lifecycle, this project is projected to generate a cumulative long-term revenue of $53 million to $138 million for the company.

$TE Fresh regulatory catalyst: On October 22, T1 announced a Commerce Department waiver supporting imports of up to 1.725 GW of solar cells. This helps protect production at G1_Dallas while the company builds its domestic cell factory. Management also reported increased demand for American solar cells and modules. Contracted demand supports expansion: The 641 MW Clearway agreement provides a customer base for modules incorporating future G2_Austin cells. T1 expects 2026 module production toward the upper end of its 3.1–4.2 GW guidance. Domestic manufacturing could unlock earnings: G2_Austin’s initial 2.1 GW phase targets first production in Q1 2027. Integrating cell and module manufacturing could improve supply security and profitability; management targets $375–450 million in annualized adjusted EBITDA at the specified integrated production scale, subject to successful execution.

$EOSE confident that the bottom is in. Should see a rebound to $2.20-2.60 in the coming weeks. Even if this goes under the lows it will not be long.

$ONDS 👇 A few few notable milestones: • Surging Backlog: Secured over $270 million in new orders since mid-2026, pushing its total pro forma backlog to $757 million. • Upward Revenue Guidance: Management raised its full-year 2026 revenue target to $525M–$550 million (representing over 10x growth compared to 2025), aiming to exit the year at a $1 billion annualized run rate. • Prime Contractor Status: Transformed into an integrated defense player through major acquisitions—such as Mistral and DZYNE—securing prime contractor status with the U.S. military. • Strategic Tech Alliances: Partnered with Palantir Technologies to develop SkyWeaver and launch Regna AI, anchoring its position in the sovereign AI and autonomous software layer. • Robust Capital Base: Maintained a massive financial cushion with $1.4 billion in cash and short-term investments to aggressively fund organic growth and acquisitions without taking on heavy debt.

$GRRR I think whatever happens in relation to number of shares - even if we go from 27 mil to 100 Mil the scaling up is vast.. if we do turnover of 200million this year.. 500 million next year.. The actual suggested figures are $1 Billion+ 2027. In 2028 the minimal figures are $2 billion + with some analysts saying turnover could be $11 Billion. So… to sum up, even based on lower levels and max dilution - you’re talking SP of $150+ within 2 years. Let that sink in. If AI stays relevant and we obtain 70% profits like they say, we could seriously be on to a winner in just 3 years.

$ASTS In a Friday statement, AST’s unit, AST & Science, proposed adding Q/V and E-band service-link capabilities to its 248-satellite network. The links would connect satellites directly to customer terminals, broadening its proposed high-frequency operations beyond ground-gateway connections. The request covers selected frequencies between 40 and 51.4 GHz, plus downlinks at 71 GHz -74 GHz and uplinks at 81GHz –84 GHz. “This supports a deployment model in which the smallest terminal classes can be used by functional mobile user equipment with varying bandwidths, powers, and antenna sizes,” AST said. The proposed services would require compatible terminals alongside AST’s core connectivity offering for standard smartphones. “AST SpaceMobile’s operations are not solely dependent on use of the E-band; AST SpaceMobile will utilize other spectrum, including the Q/V-band and 700/800 MHz bands, for its user terminals in addition to the E-band spectrum,” the filing said. Approval and interference coordination are still necessary, including protections for military users in certain bands

$DXYZ Let’s get an anthropic S-1 and an updated NAV this week!

$GLND Thread the needle. -The U.S and CRML almost struck an equity deal, which may still happen, but 15% of of their production goes to private U.S. companies. -Trump has been talking about Greenland's massive oil deposits lately. -GLND/80 Mile has the only oil & gas license in Greenland. -Robert Price confirmed the U.S has acknowleged and our monitoring our project. -There's an increasing concern about the global oil crisis, and the need to create more infrastructure and security. It seems like Trump is setting up some sort of deal with us. This is just pure conjecture on my part. But with good deductive reasoning behind it..

$CIFR Be ready. After Abbot win and audit approvals, tons of new deals ahead, not only CIPHER, but many other players also. There is no hurry to sign, terms are improving. I expect Ulysses or Odessa or Reveille deal before Q3 report or with that (not in abbot audit process). 1GW big project will be sold in December (assuming audit approval). They will start the build-out right after the approval. Massive deal ahead.

$SOAR $1.1 billion to multi-site AI infrastructure. New sites likely be announced prior Christmas .. IMO

$CRML $MP $REMX $USAR Tanbreez/CRML has Yttrium.

$UAMY Daily technical indicators are already starting to show early divergence—UAMY daily MACD histogram turned positive and its Stochastic Oscillator recently crossed out of deep oversold territory meaning that the downward selling momentum is decelerating imo

$TENX Tenax Therapeutics officially requested a Type C meeting with the FDA on October 8, 2026, following the failure of its Phase 3 LEVEL trial. Under standard FDA performance goals (PDUFA VII) for a Type C meeting, the FDA typically provides its written responses or meeting minutes within 21 days of the request if it is handled via written responses only (WRO). Counting 21 days from their October 8 filing places the expected FDA answer timeline precisely around October 29, 2026. What to Know About the Meeting • The Goal: Tenax Therapeutics is seeking the FDA's alignment on an "enrichment strategy" for its ongoing development of TNX-103 (oral levosimendan). • The Reason: While the drug missed its primary endpoint in the broad Phase 3 LEVEL trial, a prespecified subgroup of patients with more severe disease limitation (baseline 6-minute walk distance under 333 meters) showed a statistically significant 26.3-meter improvement over the placebo.

$IBRX Our good Dr. Pat us posting on a Saturday again: